MEREO BIOPH. ADR  LS-,003
MEREO BIOPH. ADR LS-,003
Depository Receipt · US5894921072 · MREO · A2PEYJ (LSSI)
Overview
2,32 EUR
-4,67 % -0,11 EUR
Lang & Schwarz (XNAS) · Current prices and charts at MoneyPeak
09.06.2025 18:10

Current Prices from MEREO BIOPH. ADR LS-,003

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
MREO
USD
09.06.2025 18:10
2,66 USD
2,74 USD
-3,14 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-4,84 % 2,81 % 8,07 % 1,44 % -34,92 % -26,57 % -2,00 %

Company Profile for MEREO BIOPH. ADR LS-,003 Depository Receipt

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Company Data

Name MEREO BIOPH. ADR LS-,003
Company Mereo BioPharma Group plc
Symbol MREO
Website https://www.mereobiopharma.com
Primary Exchange LSSI Lang & Schwarz
WKN A2PEYJ
ISIN US5894921072
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Dr. Denise Vera Scots-Knight Ph.D.
Market Capitalization 351 Mio
Country United Kingdom
Currency EUR
Employees 0,0 T
Address One Cavendish Place, W1G 0QF London
IPO Date 2019-04-24

Ticker Symbols

Name Symbol
Frankfurt MAH0.F
NASDAQ MREO

More Shares

Investors who MEREO BIOPH. ADR LS-,003 hold also have the following shares in their portfolio:
Eaton Vance New York Municipal Bond Fund Common Shares of Beneficial Interest, $.01 par value
Eaton Vance New York Municipal Bond Fund Common Shares of Beneficial Interest, $.01 par value Fund
EMIKON BL 3 LSA 23/30
EMIKON BL 3 LSA 23/30 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025